AIMEDBIO

• - AimedBio secured USD 30 million focused on advancing its ADC (antibody-drug conjugate) oncology pipeline.
• - The investment round included: Samsung Life Science Fund as a strategic investor, InterVest as a financial investor.
  • - New investors: DS Asset Management and Mint Venture Partners.
• - The funding will be used to support the clinical preparation and development of FGFR3-targeting ADC, AMB302, as well as expansion of follow-up pipeline programs targeting brain diseases.
  
  
  

Link: http://www.hitnews.co.kr/news/articleView.php?idxno=56513